Current Medicines

For more than 145 years, we have been working tirelessly to develop and deliver medicines that meet real needs.

UK laws and regulations limit the amount of product information that we can provide to the public on our website. The product information on this website is intended for UK residents over the age of eighteen years only.

Medicines

Abasaglar ®  (insulin glargine) 

Adcirca ® (tadalafil)**

Alimta ® (pemetrexed)

Baricitinib Lilly

Cialis ® (tadalafil)

Cymbalta ® (duloxetine)

Cyramza ® (ramucirumab)

Emgality ®  (galcanezumab)**

Forsteo ® (teriparatide)

Humalog ® (human insulin analogue)

Humulin ® (human insulin)

Kisunla ® ▼ (donanemab)

Lyumjev ® (insulin lispro)

Mounjaro ® ▼ (tirzepatide)

Omvoh ® ▼ (mirikizumab)

Retsevmo ® ▼ (selpercatinib)

Strattera ® (atomoxetine) 

Taltz ® (ixekizumab)

Trulicity ® (dulaglutide)

Verzenios ®  (abemaciclib)

Yentreve ® (duloxetine)

To view Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit the Electronic Medicines Compendium (EMC) website.

**Lilly is the marketing authorisation holder (MAH) but does not promote this product.

Report an Adverse Event, Product Complaint or Suspected Counterfeit Product

The following Lilly medicines are subject to additional monitoring: Kisunla ® ▼, Mounjaro ® ▼, Omvoh ® ▼ and Retsevmo ® ▼. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the Yellow Card website or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.

If you experience side effects taking a Lilly medicine, talk to your doctor or other healthcare professional. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide information on the safety of medicines. See the Yellow Card website or search for MHRA Yellow Card in the Google Play or Apple App Store for how to report side effects.

To report an adverse event, side effect or product complaint with a Lilly product, or suspected counterfeit product, please call or email Lilly UK using the information below.

PP-MG-GB-0749 June 2025